AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.
Vascular system-focused medical device maker reported sales of $80.2 million, up 12.7% year over year, beating the consensus of $74.26 million.
The report also revealed:
AngioDynamics CEO Jim Clemmer says the company is “profitable.” Its portfolio currently addresses some $10 billion in annual global market opportunities — up from $3 billion in 2021.
“With our proven commercial momentum, multiple growth catalysts, and balance sheet strength, we’re exceptionally well-positioned for sustained value creation as we move into fiscal 2026,” Clemmer added.
Guidance: AngioDynamics expects its fiscal year 2026 net sales of $305 – $310 million, versus the consensus of $304.9 million.
The medtech company expects an adjusted loss between 35 and 25 cents per share. Compare that to the consensus loss of 23 cents per share.
For the full fiscal year 2026, the company expects a $4 million-$6 million impact from tariffs. For gross margin, pro forma adjusted EBITDA, and adjusted EPS, the low end of the respective ranges assumes the highest level of tariff impact, with the high end of the respective ranges assuming the lowest level of tariff impact.
Price Action: ANGO stock is up 5.3% at $10.14 at the last check Tuesday.
Read Next:
Image: Shutterstock
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。